Disodium cromoglycate: a novel gastric antiulcer agent?
The influence of oral pretreatment with disodium cromoglycate (2.5 or 5 mg/kg X 9 doses) on the 4-h gastric effects of i.p. injected reserpine (5 mg/kg) was examined in rats. Disodium cromoglycate markedly prevented reserpine-induced ulceration, mucosal mast cell degranulation and superficial mucosal microcirculatory changes in the glandular portion of the stomach wall. These interesting results points to the possibility that disodium cromoglycate may also have gastric antiulcer effects in man.
D000818:Animals; D000897:Anti-Ulcer Agents; D004205:Cromolyn Sodium / Q000494:pharmacology*; D005260:Female; D005753:Gastric Mucosa / Q000098:blood supply / Q000166:cytology; D008407:Mast Cells / Q000187:drug effects; D008833:Microcirculation / Q000187:drug effects; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D013276:Stomach Ulcer / Q000517:prevention & control*
D000897:Anti-Ulcer Agents; D012110:Reserpine; D004205:Cromolyn Sodium